Treatment of Colonic-Type Adenocarcinoma of the Appendix

Clinical Scenario

Colonic-type adenocarcinoma of the appendix is one of several histologically distinct subtypes of appendiceal cancer — alongside mucinous adenocarcinoma, goblet cell adenocarcinoma, and neuroendocrine carcinoma. Its workup, staging, and management approach mirror that of colon cancer.

The appropriate treatment strategy depends on the extent of disease at presentation, particularly whether metastases are distant or confined to the peritoneum.

Treatment Overview

For asymptomatic patients presenting with distant metastasis, systemic chemotherapy is the recommended treatment. When metastatic spread is limited to the peritoneum and complete tumor debulking is achievable, a surgical approach combined with intraperitoneal therapy may be considered.

The full structured protocol — including selection criteria, sequencing, and the complete clinical pathway — is available in the detailed regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1055/s-0035-1564433

For the purposes of this review, appendix cancers will be broadly classified as: colonic-type adenocarcinoma, mucinous adenocarcinoma, goblet cell adenocarcinoma (GCA), and neuroendocrine carcinoma (aka. "typical carcinoid").
The workup, staging, and treatment of colonic-type adenocarcinoma arising in the appendix mirror that of colon cancer.
Systemic chemotherapy is the recommended treatment for asymptomatic patients who present with distant metastasis.
For patients with peritoneal-only metastatic disease, complete cytoreductive surgery and intraperitoneal (IP) chemotherapy should be considered if complete tumor debulking can be achieved.

View source ↗